Wikipedia

User:Mr. Ibrahem/Larotrectinib

< User:Mr. Ibrahem
Mr. Ibrahem/Larotrectinib
Clinical data
Trade namesVitrakvi
Other namesLOXO-101, ARRY-470
AHFS/Drugs.comMonograph
MedlinePlusa619006
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classTyrosine kinase inhibitor[1]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Identifiers
  • (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide
Chemical and physical data
FormulaC21H22F2N6O2
Molar mass428.444 g·mol−1
3D model (JSmol)
  • O[C@H]1CCN(C1)C(=O)Nc2cnn3ccc(nc23)N4CCC[C@@H]4c5cc(F)ccc5F
  • InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
  • Key:NYNZQNWKBKUAII-KBXCAEBGSA-N

Larotrectinib, sold under the brand name Vitrakvi, is a medication used to treat cancer.[2][3] Specifically it is used for cases that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion.[3] It is taken by mouth.[1]

Common side effects include liver problems, low red blood cells, muscle pain, tiredness, low white blood cells, diarrhea, nausea, and fever.[3] Other side effects may include numbness, tremor, and delirium.[1] Use in pregnancy may harm the baby.[3] It is a tyrosine kinase inhibitor of TrkA, TrkB, and TrkC.[1]

Larotrectinib was approved for medical use in the United States in 2018, Europe in 2019, and Australia in 2020.[1][5][2] In the United Kingdom it costs the NHS about £15,000 a month as of 2021.[4] In the United States this amount is about 34,000 USD.[6]

References edit

  1. ^ a b c d e "Larotrectinib Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 21 November 2021.
  2. ^ a b c "Vitrakvi". Therapeutic Goods Administration (TGA). 16 September 2020. Archived from the original on 19 September 2020. Retrieved 22 September 2020.
  3. ^ a b c d e "Vitrakvi- larotrectinib capsule Vitrakvi- larotrectinib solution, concentrate". DailyMed. 26 July 2019. Archived from the original on 7 April 2021. Retrieved 22 September 2020.
  4. ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1031. ISBN 978-0857114105.
  5. ^ "Vitrakvi EPAR". European Medicines Agency (EMA). 23 July 2019. Archived from the original on 2 October 2020. Retrieved 22 September 2020.
  6. ^ "Vitrakvi Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 21 April 2021. Retrieved 21 November 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Larotrectinib&oldid=1209025602"